Novavax’s coronavirus vaccine proves more than 90 percent effective

Novavax’s coronavirus vaccine proved to be 90.4 percent effective in preventing COVID-19 cases, putting it on the same playing field as highly effective mRNA shots, the company announced Monday.

The protein-based vaccine also proved to be 100 percent effective in preventing moderate and severe disease in phase 3 trials.

The trials, which included 29,960 people in the U.S. and Mexico, were conducted when more transmissible variants were spreading, and the Alpha variant, first discovered in the U.K., became dominant in the U.S. These results showed the vaccine could be highly effective — around 93 percent — against new variants, the release noted.

The company also said its vaccine — which doesn’t need to be stored at ultra-low temperatures — was 100 percent effective against the earlier virus variants.

Novavax will submit its vaccine candidate to regulators for approval in third quarter of the year, by the end of which the company said it can make 100 million doses per month. By the end of 2021, it will be able to make 150 million doses a month.

However, limited production capacity in Europe has held up a purchasing deal with the EU. The Commission and company concluded “exploratory talks” in December to purchase up to 200 million doses but have not completed a deal.

This article is part of POLITICO’s premium policy service: Pro Health Care. From drug pricing, EMA, vaccines, pharma and more, our specialized journalists keep you on top of the topics driving the health care policy agenda. Email [email protected] for a complimentary trial. 

 168 total views,  2 views today

Share this on social media

Leave a Reply



Click one of our representatives below to chat on WhatsApp or send us an email to

× How can I help you?
%d bloggers like this: